🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 74019P207 (prev. 74019P108 )
- Market Cap
- Mid Cap
- IPO
- 3/28/2019 · $16.00/share
Business: Precision BioSciences, Inc. is dedicated to improving life through its proprietary genome editing platform, ARCUS. Precision leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and create healthy and sustainable food and agriculture solutions. Precision is actively developing product candidates in three innovative areas: allogeneic CAR T immunotherapy, in vivo gene correction, and food.
Notes: Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that its Board of Directors has approved a 1-for-30 reverse stock split of the Company’s common stock. The reverse stock split will become effective at 5:00 p.m. Eastern Time on February 13, 2024, after close of trading on The Nasdaq Capital Market. The Company’s common stock is expected to commence trading on a split-adjusted basis when the markets open on February 14, 2024 under the existing trading symbol “DTIL.” The new CUSIP number for the Company’s common stock following the reverse stock split will be 74019P207.
Company Contact
- CEO
- Michael Amoroso
- CFO
- Naresh Tanna
- Headquarters
- 302 East Pettigrew St., Suite A-100, Durham, NC 27701
- Phone
- 919-314-5512
- Investor Relations
- Naresh Tanna · 919-314-5512 · naresh.tanna@precisionbiosciences.com